← brief for 2026-10-11 · Slowing decline

Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide.

Article C Peer reviewed Observational

Key takeaways

This study looked at people taking very low doses of two weight-loss drugs. It used records from 29 million patients. It shows a link between low doses and certain health effects. It does not prove that low doses cause these effects.

Who did this work

Murugadoss K · Venkatakrishnan AJ · Soundararajan V

Source

Article · PubMed, the drug frontier · 2026 Aug 31
https://pubmed.ncbi.nlm.nih.gov/42857675/